Oncology study for non-small cell lung cancer (S17AGE07)

The purpose of this research study is to assess safety and tolerability, pharmacokinetics and general activity of the combination of two drugs, AGEN1884 and Pembrolizumab. This type of testing measures how the drug works in the body, the relationship between the amount of the drug taken and the effect on the body, and the effect the drugs have on your tumour.

Pembrolizumab is approved in Australia for the treatment of metastatic non-small cell lung cancer (NSCLC) that is positive for PD-L1, marker on the tumour. It is known as Keytruda™. This study uses Pembrolizumab in combination with AGEN1884 (study drug) which is not approved. Therefore, it is an experimental treatment for metastatic NSCLC. This means that it must be tested to see if it is an effective treatment for metastatic NSCLC.

In the past two decades, researchers have demonstrated the importance of the immune system in controlling cancer. A number of drugs that target the immune system and activate it to “fight” cancer, are being developed. There is some evidence that the proposed regimen for this research study is more effective and may have a better safety profile than other combination regimens.

Both AGEN1884 and Pembrolizumab are immunotherapies that activate the immune system to detect and flight the cancer cells. AGEN1884 is given every 6 weeks and pembrolizumab is given every 3 weeks, via intravenous infusion. The treatment may continue for as long as there is clinical benefit up to 24 months.

This clinical study is currently recruiting.

If you would like more information, register below or call 1800 727 874.

No inpatient stay required

14 visits over the first 12 weeks, then every 3 weeks thereafter

* have metastatic Non–Small Cell Lung Cancer (NSCLC)
* have over-expression of a protein called PDL1
* have not received prior drug treatment.

When enquiring about this clinical study please quote the study code above